Pediatric pharmacology

Journal Information
ISSN / EISSN : 1727-5776 / 2500-3089
Current Publisher: Paediatrician Publishers LLC (10.15690)
Total articles ≅ 639
Current Coverage
DOAJ
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Marietta V. Manucharyan, Tatiana V. Turti, Irina A. Belyaeva, Tatiana E. Privalova, Ludmila M. Makarova, Marina A. Ovsyannikova
Published: 23 September 2020
Pediatric pharmacology, Volume 17, pp 345-351; doi:10.15690/pf.v17i4.2167

Abstract:
Background. The incidence of sepsis among newborns ranges from 1–12 to 38 per 1,000 live births in the world according to scientific literature [1, 2]. The clinical case demonstrates the features of the newborn organism sensitivity and the therapeutic and diagnostic process difficulties.Clinical case description. The boy was born on the 37th week of gestation, 1st of twins, with body weight 3330 g, height 51 cm, APGAR score 8/9 points. He was on breastfeeding. His condition has deteriorated rapidly on the 9th day of life. The condition was severe due to intoxication syndrome, necrotising enterocolitis (NEC) manifestation, further development of systemic inflammatory response syndrome and multiple organ dysfunction syndrome. Severe pain syndrome and movement restraint in limbs have appeared on the 20th day of life. X-ray imaging: NEC signs, multiple osteomyelitis foci in the limbs.Conclusion. Modern adequate diagnosis and justified treatment tactics have led to positive outcome: child’s condition has improved, body weight has increased, pain syndrome has been managed, the volume of movements in the limbs has increased, inflammatory markers have stabilised. The child was discharged from hospital in satisfactory condition at the age of 2 months.
Anvar A. Dzhumagaziev, Dina A. Bezrukova
Published: 23 September 2020
Pediatric pharmacology, Volume 17, pp 328-333; doi:10.15690/pf.v17i4.2165

Abstract:
The review of the literature is mostly based on its own research and is devoted to the influence of natural (bottomland, 28 m below sea level, climate conditions with severe changes in temperature during the year, biogeochemical province with moderate iodine deficiency) and anthropogenic (increased air, water and soil pollution) environmental factors on children’s health in the Astrakhan region. The impact of the Astrakhan gas condensate field on the health condition is shown: growing number of children with physical and psychomotor disorders, imbalance in cellular and humoral immunity factors, growing number of frequently ill children with problems in adaptation to kindergartens and schools. The influence of vehicles on environmental pollution, frequency of allergic diseases among children (asthma, allergic rhinitis, atopic dermatitis), and degraded quality of life was noted. There is the negative situation with water sources: samples from main Volga riverbed show both non-organic and organic contamination. Contamination of drinking water is considered as serious factor increasing the incidence of atopic pathology. The correlation between the prevalence of atopic dermatitis and soil contamination with benzapyrene on the territory of these children residence was revealed. Complex influence of iodine deficiency and adverse anthropogenic factors leads to abnormal children’s blood composition: development of erythrocytosis, leukocytosis, inhibition of hemoglobin synthesis function, lymphopenia. The incidence of diffusenodular endemic goiter, subclinical hypothyroidism and thyroiditis can increase as well. It is necessary to develop prevention and rehabilitation measures for children diseases associated with combined adverse effect of natural and anthropogenic factors in the Astrakhan region.
Nikolay N. Murashkin, Roman A. Ivanov, Dmitri V. Fedorov, Eduard T. Ambarchyan, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Alena A. Savelova
Published: 23 September 2020
Pediatric pharmacology, Volume 17, pp 334-339; doi:10.15690/pf.v17i4.2160

Abstract:
Atopic dermatitis (AD) is one of the common multifactorial inflammatory diseases manifesting predominantly in childhood. There is significant number of cases of self-regression of the disease with aging. On the other hand, there is also another scenario ending with AD persistent course and/or development of comorbid allergic pathologies that can significantly worsen patient’s quality of life and finally lead to social maladjustment. The pathogenesis of such way includes epidermal barrier disturbance, transcutaneous sensibilisation and aberrant allergic (Th2) immune systemic response development. Main role in preventing of this pathological pathway is lying on the new class of moisturizers containing active components "emollients plus". They are considered as foundation for the therapy and prevention of the development of AD and other allergic diseases. This literature review provides relevant data on AD pathogenesis and development of comorbid allergic pathologies. This paper also covers data on the effect of emollients in restoration of the epidermal barrier and their use as preventive measures.
Article Editorial
Published: 23 September 2020
Pediatric pharmacology, Volume 17, pp 360-415; doi:10.15690/pf.v17i4.2169

Abstract:
Организационный комитет форума представляет работы студентов и молодых ученых, принятые научной комиссией, включающей профессорско-преподавательский состав кафедр Клинического института детского здоровья им Н.Ф. Филатова ФГАОУ ВО Первый МГМУ им И.М. Сеченова Минздрава России (Сеченовский Университет).
Alexander A. Baranov, Leyla S. Namazova-Baranova, Andrey N. Surkov, Olga S. Gundobina, Elena A. Vishneva, Tea V. Margieva, Nato D. Vashakmadze, Liliya R. Selimzyanova
Published: 23 September 2020
Pediatric pharmacology, Volume 17, pp 303-317; doi:10.15690/pf.v17i4.2159

Abstract:
Glycogen storage disease is the hereditary carbohydrate metabolism pathology which is caused by mutations in various genes encoding enzymes responsible for glycogenesis and glycogenolysis. Excessive glycogen deposition in various tissues cells (mostly in liver and muscles) occurs due to enzyme defects. The authors present recent epidemiological data and features of glycogen storage disease etiology and pathogenesis. Clinical characteristics of different types of this disease are also presented. The data on laboratory-instrumental and morphological signs of glycogen storage disease in children, as well as data on its treatment methods is provided in accordance with the developed clinical guidelines. The article provides relevant information on disease types with predominant liver involvement, besides the variety of clinical forms of glycogenosis.
Irina I. Spichak, Larisa V. Moiseeva, Irina P. Karimova, Rafiia K. Babik, Galina N. Kireeva
Pediatric pharmacology, Volume 17; doi:10.15690/pf.v17i3.2125

Abstract:
Сообщение о случае бессимптомного SARS-CoV-2-носительства у пациента детского возраста с тяжелым хроническим заболеванием
М. Петтоелло-Мантовани, Julije Mestrovic, Mehmet Vural, Leyla Namazova-Baranova
Pediatric pharmacology, Volume 17, pp 234-235; doi:10.15690/pf.v17i3.2128

Abstract:
Президенты и представители различных европейских педиатрических сообществ и ассоциаций собрались в Стамбуле (Турция) в декабре 2019 года, чтобы переизбрать Исполком Европейской педиатрической ассоциации (European Paediatric Association, EPA), являющейся Союзом национальных европейских педиатрических сообществ и ассоциаций (Union of National European Paediatric Societies and Associations, EPA/UNEPSA). Вновь избранный Совет будет активно участвовать в работе Союза европейских педиатрических организаций, особенно в таких областях педиатрии, как научные исследования, подготовка и обучение кадров, передача знаний и опыта, поддержание здоровья и благополучия детей. Основные усилия нового Совета будут направлены на усовершенствование систем здравоохранения в Европе, развитие образовательных программ, призванных помочь подготовить высококвалифицированных специалистов, которые смогут справиться со всевозможными проблемами своих пациентов и стать настоящими экспертами в области охраны здоровья детей и подростков.
Pediatric pharmacology, Volume 17, pp 162-178; doi:10.15690/pf.v17i3.2121

Abstract:
Dear friends, colleagues! The number of cases of new coronaviral infection has begun to decrease over the past two months, whereas, the number of publications on the accumulated experience of diagnosis, management and rehabilitation is increasing. It allows us to share knowledge and enhance our tactics. We present updated data on SARS-CoV-19 coronavirus and the disease it causes in this review.
Marina G. Kantemirova, Yulia Yu. Novikova, Dmitry Yu. Ovsyannikov, Seda Kh. Kurbanova, Anastasia A. Glazyrina, Olga A. Korovina, Antonina A. Rakhalina, Yulia V. Romanova, Alexey Yu. Rtishchev, Andrey V. Kharkin, et al.
Pediatric pharmacology, Volume 17, pp 219-229; doi:10.15690/pf.v17i3.2126

Abstract:
Background. New coronaviral infection (COVID-19) in most cases has less severe course in children than in adults. However, there were reports from the number of European countries and from United States (from March 2020) about children with new disease with signs of Kawasaki disease (KD) and toxic shock syndrome (TSS). So it has received one of the names children’s multisystem inflammatory syndrome (CMIS) associated with COVID-19. The aim of the study is to summarize up-to-date information about this disease.Methods. Information search in PubMed database, CDC (USA) and WHO websites, Search for information in PubMed database, on CDC (USA) and WHO websites, analysis of the medical records of observed patient with CMIS.Results. Clinical and laboratoryinstrumental manifestation and outcomes of CMIS in 120 children from Italy, France, Switzerland, England, USA with similar signs were analyzed. Proposed international diagnostic criteria of the disease in comparison with other phenotypically similar diseases (KD, shock syndrome at KD, TSS of Staphylococcal and Streptococcal etiology, macrophage activation syndrome), clinical observation of patient, algorithm of evaluation and management of patients with CMIS are presented.
Pediatric pharmacology, Volume 17, pp 179-186; doi:10.15690/pf.v17i3.2122

Abstract:
Background. Recurrent spontaneous urticaria (RSU) is rare in children, thus, it is debilitating condition that always requires treatment. There are several limitations on the drugs use in children with RSU. Omalizumab is the effective medication for achieving the control of RSU, used in adolescents over 12 years of age.The aim of the study is to compare the efficiency of various approaches for RSU management in children.Methods. The three-year comparative study of patients with RSU aged from 1 to 17 years managed only with 2nd generation antihistamines in standard or increased doses for at least 3 months and patients managed in addition to standard treatment with omalizumab (300 mg once in 4 weeks subcutaneously) was conducted. The essential treatment outcomes are achieving control of the disease (UAS7 = 0) in 6 months and remission maintaining after 36 months of observation. Additional outcomes are decrease in the number of aggravations that required the use of glucocorticosteroids (GCS) during 3 years of followup; analysis of treatment outcomes of patients with severe urticaria in subgroups (including UAS7 levels).Results. The frequency of disease control (UAS7 = 0) by 6 months of therapy was significantly higher in patients of the omalizumab group — 76%, in the second group — 0%. The UAS7 in the omalizumab group was 0 (0; 1) points, in the group of patients on standard therapy — 13 (10; 16) points (p < 0.05). Remission was observed in 53% of patients (9 people) in the omalizumab group in 36 months, in the comparison group — in 32% (13 people), p = 0.129; UAS7 in the omalizumab group was 0 (0; 8.5) points, in the comparison group — 8 (0; 13) points, p = 0.076. The use of systemic GCS for acute treatment decreased during 3 years of follow-up: in the omalizumab group — from 41 to 5.9%, in the group on 2nd generation antihistamines — from 46 to 19% (p = 0.258). The result of subgroup analysis was similar.Conclusion. Adding omalizumab to standard RSU therapy makes it possible to achieve control of the disease reliably faster in most cases. There was gradual decrease in RSU activity in the group on standard therapy during the 3-year follow-up: spontaneous remission was mentioned in 32% of children within 3 years.
Back to Top Top